Surface Oncology, Inc. (NASDAQ:SURF) CFO Jessica Fees Sells 5,980 Shares

Surface Oncology, Inc. (NASDAQ:SURFGet Rating) CFO Jessica Fees sold 5,980 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $1.72, for a total transaction of $10,285.60. Following the transaction, the chief financial officer now owns 111,349 shares in the company, valued at $191,520.28. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Surface Oncology Trading Down 1.1 %

Shares of NASDAQ:SURF traded down $0.02 during trading on Friday, reaching $1.78. 857,629 shares of the company were exchanged, compared to its average volume of 717,498. The firm has a market capitalization of $97.21 million, a PE ratio of -1.38 and a beta of 1.60. The business’s fifty day simple moving average is $1.80 and its 200-day simple moving average is $2.48. Surface Oncology, Inc. has a 12-month low of $1.37 and a 12-month high of $8.38. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.42 and a quick ratio of 9.42.

Surface Oncology (NASDAQ:SURFGet Rating) last issued its earnings results on Monday, May 9th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.61. The business had revenue of $30.00 million for the quarter. Surface Oncology had a negative net margin of 182.63% and a negative return on equity of 47.56%. On average, research analysts anticipate that Surface Oncology, Inc. will post -1.19 EPS for the current year.

Hedge Funds Weigh In On Surface Oncology

A number of institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new position in shares of Surface Oncology during the first quarter valued at approximately $27,000. Formidable Asset Management LLC bought a new position in shares of Surface Oncology during the first quarter valued at approximately $33,000. Delphia USA Inc. bought a new position in shares of Surface Oncology during the first quarter valued at approximately $36,000. Forefront Analytics LLC bought a new position in shares of Surface Oncology during the first quarter valued at approximately $62,000. Finally, Eagle Rock Investment Company LLC bought a new position in shares of Surface Oncology during the fourth quarter valued at approximately $105,000. 70.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Jonestrading reiterated a “buy” rating and set a $12.00 price target on shares of Surface Oncology in a report on Sunday, June 5th.

Surface Oncology Company Profile

(Get Rating)

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8.

See Also

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.